Advertisement
Research Article

Praziquantel Treatment Decreases Schistosoma mansoni Genetic Diversity in Experimental Infections

  • Regina Coeli,

    Affiliation: Genomics and Computational Biology Group, Centro de Pesquisas René Rachou, Fiocruz, Belo Horizonte, Minas Gerais, Brazil

    X
  • Elio H. Baba,

    Affiliation: Laboratory of Schistosomiasis, Centro de Pesquisas René Rachou, Fiocruz, Belo Horizonte, Minas Gerais, Brazil

    X
  • Neusa Araujo,

    Affiliation: Laboratory of Schistosomiasis, Centro de Pesquisas René Rachou, Fiocruz, Belo Horizonte, Minas Gerais, Brazil

    X
  • Paulo M. Z. Coelho,

    Affiliation: Laboratory of Schistosomiasis, Centro de Pesquisas René Rachou, Fiocruz, Belo Horizonte, Minas Gerais, Brazil

    X
  • Guilherme Oliveira mail

    oliveira@cpqrr.fiocruz.br

    Affiliations: Genomics and Computational Biology Group, Centro de Pesquisas René Rachou, Fiocruz, Belo Horizonte, Minas Gerais, Brazil, National Institute of Science and Technology in Tropical Diseases, Centro de Pesquisas René Rachou, Fiocruz, Belo Horizonte, Minas Gerais, Brazil

    X
  • Published: December 19, 2013
  • DOI: 10.1371/journal.pntd.0002596

Abstract

Background

Schistosomiasis has a considerable impact on public health in many tropical and subtropical areas. In the new world, schistosomiasis is caused by the digenetic trematode Schistosoma mansoni. Chemotherapy is the main measure for controlling schistosomiasis, and the current drug of choice for treatment is praziquantel (PZQ). Although PZQ is efficient and safe, its repetitive large-scale use in endemic areas may lead to the selection of resistant strains. Isolates less susceptible to PZQ have been found in the field and selected for in the laboratory. The impact of selecting strains with a decreased susceptibility phenotype on disease dynamics and parasite population genetics is not fully understood. This study addresses the impact of PZQ pressure on the genetics of a laboratory population by analyzing frequency variations of polymorphic genetic markers.

Methodology

Infected mice were treated with increasing PZQ doses until the highest dose of 3×300 mg/Kg was reached. The effect of PZQ treatment on the parasite population was assessed using five polymorphic microsatellite markers. Parasitological and genetic data were compared with those of the untreated control. After six parasite generations submitted to treatment, it was possible to obtain a S. mansoni population with decreased susceptibility to PZQ. In our experiments we also observed that female worms were more susceptible to PZQ than male worms.

Conclusions

The selective pressure exerted by PZQ led to decreased genetic variability in S. mansoni and increased endogamy. The understanding of how S. mansoni populations respond to successive drug pressure has important implications on the appearance and maintenance of a PZQ resistance phenotype in endemic regions.

Author Summary

Schistosomiasis causes severe health problems and economic losses in transmission areas in the Americas, Africa, and Southeast Asia. In regions where treatment is available, such as Brazil, chemotherapy has led to decreased morbidity of the disease. However, parasite resistance to drugs is of general concern. Drug resistance is known in some species of helminths, and there are reports of decreased susceptibility in schistosomes, although such reports are not widespread. The impact of consecutive drug treatment on parasite populations at transmission sites can be evaluated by the genetic makeup of the population. For example, the decrease in the genetic diversity of these populations upon chemotherapy can be interpreted as the selection of less sensitive parasites. In this study, we used a laboratory mouse model of schistosomiasis that was treated with increasing amounts of praziquantel (the drug of choice for human treatment) until we reached the highest dose of 3×300 mg PZQ/kg. Our results clearly indicate that the parasite population showed a decrease in genetic diversity after measuring allelic and genetic diversity. This observation confirms that drug selection occurred in this population. The work highlights the need for genetic monitoring of populations under drug pressure, resistance mechanisms, and the dynamics of parasite populations upon treatment.

Introduction

Schistosomiasis is a disease that affects approximately 206 million people in 76 countries. On a global scale, 779 million people are at risk of contracting the disease [1]. Currently, the main approaches for the reduction of schistosomiasis morbidity are the treatment of infected patients and sanitation [2]. The life cycle of the parasite is complex, involving a vertebrate host and a snail vector. Infection occurs when parasites in the infective stage (cercariae) are released from aquatic snails and penetrate the skin or mucosa of the vertebrate host upon contact with water. By migrating through the circulatory system, the larvae (schistosomula) reach the portal hepatic vein where they mature into adult worms and migrate to the mesenteric veins. The female then deposits eggs in the intestinal vein system. Some eggs pass through the gut lumen and are eliminated with the feces, or urine in the case of S. haematobium, while others are trapped in the host tissues where they produce a granulomatuous immune-inflammatory process that represents the main cause of pathology [3].

Praziquantel (PZQ) is the drug used for treatment of human schistosomiasis and is inexpensive and effective against all human schistosome and some cestode species [4]. However, PZQ is less effective against the immature stages of Schistosoma mansoni [5]. PZQ appears to exert multiple effects on schistosomes, damaging the tegument and causing muscle contraction [6]. These morphological alterations are accompanied by an increased exposure of parasite antigens on the worm surface, which in turn appears to render the worms more susceptible to attack by the immune system [7]. The relationship between PZQ and Ca+2 influxes suggests that the sites of action are Ca2+ ion channels in the membrane of tegument and muscle cells [8], [9], [10]. Other effects of PZQ in Schistosoma that have been demonstrated include the following: reduction in the level of glutathione (GSH) [11]; inhibition of the male excretory system [12]; inhibition of nucleoside uptake [13]; and increase in MDR transporter activity [14], [15]. However, a complete description of PZQ's mode of action has not yet been accomplished.

The availability of only one drug to treat schistosomiasis is a concern, and too little investment has been made toward the development of alternatives [16]. There is some natural variation in the parasite sensitivity to PZQ. The variability of S. mansoni strains regarding susceptibility to schistosomicidal drugs was demonstrated in different endemic regions, such as Senegal, Egypt and Brazil [17], [18], [19], [20], [21], [22], [23]. It is conceivable that in an endemic situation a resistant phenotype may be selected for under frequent drug pressure [18]. Resistant, less susceptible isolates or parasites that survive treatment of S. mansoni in endemic regions may emerge by different mechanisms. The main causes may be high parasitic loads, fast reinfection, the presence of immature worms, inefficient human immune responses, the use of low quality drugs, differences in evaluation, and cure criteria or actual drug resistance [24], [25].

The first study that showed it is possible to induce S. mansoni less susceptible to PZQ was published by Fallon and Doenhoff [26]. Recently, PZQ resistant populations were also obtained after the intramolluscan parasite phase was exposed to the drug [27]. The genetics of S. mansoni populations are being investigated with the use of highly polymorphic microsatellite markers [28]; the availability of a genetic MAP significantly contributed to these efforts [29]. Polymorphic microsatellites have proven to be extremely useful in describing the genetic structure of field and laboratory isolates [30], [31], [32], [33], [34]. However, little is known about the genetics of PZQ susceptibility [35], [36].

Understanding how drug pressure affects the genetic structure of a parasite population in a controlled setting raised questions relevant to the endemic setting related to transmission, chemotherapy effects, and epidemiology of the disease [35], [36], [37]. Studies of how Schistosoma populations at endemic sites perform under drug pressure are necessary for determining the most efficient treatment strategy for infected populations and for the design and modeling of control programs [38], [39]. Because PZQ is the drug of choice being used in the population control of schistosomiasis, studies about the genetics of populations under drug pressure and new drug targets are urgently needed. In this paper, we hypothesize that in a mouse system, as a result of a regimen of exposures to increasing amounts of PZQ, the S. mansoni population will experience a decrease in genetic diversity and susceptibility to the drug.

Materials and Methods

Ethics statement

In vivo studies were conducted in compliance with the guidelines of the Collegiate of Animal Experimentation (COBEA) and approved by the Commission on the Ethical Use of Animals (CEUA-FIOCRUZ) protocol number L-018/09 approved on Jan. 23, 2009.

Parasites and hosts

The S. mansoni (LE strain) life cycle was maintained using Biomphalaria glabrata snails as intermediate hosts and Swiss mice as definitive hosts according to Pellegrino and Katz [40]. Female albino mice weighing approximately 20 g were infected with 100±10 cercariae of S. mansoni (LE strain) by a subcutaneous route.

Induction of decreased susceptibility to PZQ

To induce decreased susceptibility, increasing doses of an aqueous suspension of PZQ were administered to infected mice by oral gavage. The protocol used for parasite selection was based on Fallon and Doenhoff [26] with one modification: in the third treatment, mice were given two doses of 200 mg/kg. The dose of 200 mg/kg PZQ was used to ensure that some of the parasites survived drug treatment for subsequent passages until the highest dose of 3×300 mg/kg was reached. The first and second rounds of treatment started with two subsequent doses of 100 mg/kg on days 28 and 35 after infection. The eggs produced by the worms that survived drug treatment were used to infect snails, which, after 35 days, started to eliminate cercariae that were used to infect mice. For the third and fourth rounds of treatment, subsequent doses of 2×200 mg/kg on days 28 and 35 were used. At the fifth treatment round, mice were treated with two doses of 250 mg/kg and after the sixth round, treatment was maintained with three doses of 300 mg/kg on days 28, 35 and 37 until the treatment rounds were completed. Five weeks after each round of PZQ treatment the mice were portally perfused and the surviving worms recovered were counted. The worm population obtained after seven successive treatment rounds was considered the Selected population (S). For each round of PZQ treatment the same procedure was used in a group of mice infected with cercariae produced by snails from the Non-selected population (N). Adult worms in the Selected and Non-selected groups were retrieved by perfusion of the portal system with 0.85% saline solution and 1% heparin [41]. Four groups of 20 mice were used for each cycle. Two groups (Selected and Non-selected populations) were left untreated and animals were portally perfused 45 days after infection to obtain an infection control worms count. The other two groups were treated as described above and mice were sacrificed five weeks after treatment.

DNA extraction

For DNA extraction of individual parasites, worm pairs were separated and digested in extraction buffer (50 mM Tris-HCl pH 8.0, 100 mM EDTA, 100 mM NaCl and 0.5% SDS) and 20 µg/ml of proteinase K (Sigma) and incubated for 12 hours at 37°C, followed by incubation at 95°C for 5 min. Nucleic acids were precipitated with cold absolute ethanol and resuspended in 30 µl of TE buffer and rehydrated for 12 hours at 4°C.

Amplification of microsatellite loci

We analyzed five polymorphic microsatellite loci for each population. Allelic and genotypic data were identified for a total of 250 worms. PCR reactions and scoring of the polymorphic microsatellites were conducted as previously described [42], [43]. Primer pairs and genomic locations are described in Table 1.

thumbnail

Table 1. Primers used for microsatellite genotyping, and genomic localization.

doi:10.1371/journal.pntd.0002596.t001

Genetic analysis

Genetic data was analyzed with the Fstat software version 2.9.3.2 [44]. For each locus, allelic and genotypic frequencies, linkage disequilibrium among polymorphic loci, the inbreeding coefficient, and observed and expected heterozygosity values were calculated. Hardy-Weinberg (HW) equilibrium was calculated using the Arlequin software [45]. Population structure was estimated for the isolates using the fixation indices Fst [46], Fis [47] and Rst [48]. The Guo and Thompson test [49] was used to evaluate significance of deviations of the observed and expected heterozygosity between Selected and Non-selected worms and to assess the difference between genetic variability of male and female worms (P≤0.05). Statistical analysis of parasitological data was conducted with the SPSS software version 11. The mean number of worms recovered after selection or lack of selection by PZQ was compared using the Mann-Whitney and Kruskall-Wallis tests. To evaluate the significance between female and male worm burdens, the Wilcoxon test was used. P-values≤0.05 were considered to be statistically significant. The percent reduction of worm burden in each treatment group was calculated according Cioli et al. [23]. Approximately 200 worms each from treated and untreated mice were used to produce the genetic data.

Results and Discussion

Parasitological data

PZQ selection resulted in a striking increase in the number of recovered parasites after treatment with this drug, compared with the number recovered after equivalent treatment of non-selected parasites. Thus, after seven parasite generations of selection using doses of PZQ that increased from 200 mg/kg to 900 mg/kg, we observed a greater than three-fold increase in the degree to which the proportion of worm load in the Non-selected group had been reduced by drug treatment (47.3%), compared with the level of reduction in the Selected group (14.58% - Table 2). These findings are in agreement with previous observation of laboratory selection reported by Fallon and Doenhoff [26].

thumbnail

Table 2. Worms recovered and the percentage of worm reduction after PZQ pressure.

doi:10.1371/journal.pntd.0002596.t002

Female adult worms were shown to be more susceptible than males to PZQ exposure. We observed that after exposure to 3×300 mg/kg of PZQ, both male and female worms showed a significant decrease in susceptibility. Table 3 shows the results obtained after treatment of infected mice with 3×300 mg/kg doses of PZQ after 11 passages, indicating the increased sensitivity of female adult worms in comparison to male worms. After treatment, the male to female ratio changed from 2.5 in the control population to 8.7 in the Selected population. A decreased recovery of males was observed by Delgado et al. [50]. It has been observed that tegumental damage induced by PZQ is more apparent in male worms, while the female tegument displays limited damage [51]. Pica-Mattoccia and Cioli [52] observed that immature females are refractory to PZQ treatment, but upon sexual maturation they become sensitive to PZQ. The same researchers showed that in vitro males displayed higher sensitivity to PZQ. These experiments differ from ours in that we assessed PZQ sensitivity in vivo. It has been suggested that the environment in which the parasite is located affects the parasite physiology and drug sensitivity [52]. This is especially relevant for females living in the gynecophoric canal of males, where they may be more protected from PZQ activity. It has also been reported that resistance can lead to decreased reproductive fitness in schistosomes [53], [38]. Previous laboratory studies show that selection can rapidly change infectivity, virulence phenotypes, and population structure of schistosomes after a few generations [34]. The decrease in the female population was so striking after 11 passages that it resulted in the impossibility to maintain the strain in the laboratory. Our study shows that in a short time PZQ can select against female parasites, and such variations may substantially influence transmission dynamics, thereby decreasing the spread of decreased susceptibility to PZQ.

thumbnail

Table 3. Ratio of male/female adult worms recovered from the Non-selected and Selected populations after 11 passages.

doi:10.1371/journal.pntd.0002596.t003

Genetic data

PZQ-mediated selection led to decreased allelic diversity in S. mansoni. The number of alleles found in the Non-selected population decreased in the Selected population from 98 to 42. The number of genotypes found in the Non-selected population and the Selected population decreased from 265 to 112. The allele and genotype number for each locus decreased after successive treatments. The Selected population (S) showed a lower total number of alleles per genotype locus than that of Non-selected parasites (Table 4). It was clearly demonstrated that the selection process decreased parasite genetic diversity.

thumbnail

Table 4. Allele and Genotype numbers in Non-selected (N) and Selected (S) populations.

doi:10.1371/journal.pntd.0002596.t004

The degrees of population structuring and diversity among Selected and Non-selected populations were evaluated by genetic diversity analysis (Rst) and Inbreeding Coefficient (Fis). Our results show that there is a significant genetic differentiation between the first and seventh generations of the S population (Rst = 0.240). In contrast, without PZQ pressure, we did not observe a significant differentiation in the Non-selected populations (Rst = 0.080). Genetic diversity data reveal that decreased susceptibility selection contributes to the decrease of genetic variability of parasites selected with PZQ. Next, we measured the level of inbreeding between the Selected and Non-selected populations. According to Wright [47], a Fis value of 0.309 indicates a high level of inbreeding in the Selected population. The Fis index shows that there is a strong increase in endogamy in the Selected population (0.134 to 0.309). Our results with both indexes suggest that the Selected S. mansoni population is less genetically diverse as a result of PZQ pressure. These results agree with a report by Norton and colleagues [36], which showed that in an endemic setting a single round of mass drug administration to a human population produced a genetic bottleneck on S. mansoni. We did not observe significant differences in the genetic variability of male and female worms (data not shown) nor in populations passaged in parallel but not submitted to drug pressure.

The analysis of Hardy-Weinberg equilibrium deviation is an important resource for the study of the evolutionary mechanisms that can act upon a given population. The comparisons between the expected and observed heterozygosities in Selected and Non-selected populations show that the observed heterozygosity was lower than expected for all polymorphic loci except SmBr 9 in the N strain (Table 5). HW equilibrium deviation occurred in the majority of analyzed loci along with the loss of observed heterozygosity in the S and N populations. The analysis of the genetic structure of the N and S populations using the Hardy-Weinberg coefficient agrees with the genetic diversity index and endogamy coefficient and indicates decreased genetic diversity in the population under drug pressure. The maintenance of the S. mansoni LE strain by PZQ-mediated selective pressure contributed to the decrease in variability of the S population. The genetic bottleneck and subsequent loss in genetic diversity were also observed in parasites found at endemic sites that had received PZQ treatment [36]. One explanation for the observed deficiency in heterozygosity in the Selected population could be selective pressures suffered by this strain after seven generations under drug pressure [39]. Taken together, these results may indicate that at endemic sites, there may be a larger pool from which genetically resistant strains may be positively selected under drug pressure.

thumbnail

Table 5. Expected and observed heterozygosity in the Selected and Non-selected populations.

doi:10.1371/journal.pntd.0002596.t005

In this paper, we clearly demonstrate the effects of PZQ selection on populations displaying decreased susceptibility to PZQ. We observed a decrease in the genetic diversity of the parasite. In addition, the apparent cost of coping with large doses of PZQ is an imbalance in the male/female ratio. In the laboratory, the consequence was the difficulty of maintaining the strain. Although PZQ may cause changes in the genetic structure of treated populations, our results suggest a slow spread of drug resistance because after 11 rounds of treatment we recovered almost exclusively female worms. Levels of genetic diversity, as opposed to genetic divergence between populations, may itself be an important component of the epidemiology of infection and disease, as well as a key indicator for monitoring the effects of selection imposed by drug treatment (36). We speculate that in the field, one possible reason for resistance or decreased susceptibility not being widespread is perhaps its biological cost. The creation of a genetic map constructed using microsatellites, combined with the future development of a SNP map, means that genetic tools will be invaluable in both investigating the genetic profile of populations and identifying markers or genes that convey resistance.

Author Contributions

Conceived and designed the experiments: RC EHB NA PMZC GO. Performed the experiments: RC EHB NA PMZC GO. Analyzed the data: RC EHB NA PMZC GO. Contributed reagents/materials/analysis tools: PMZC GO. Wrote the paper: RC EHB NA PMZC GO.

References

  1. 1. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J (2006) Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis 6 (7) 411–25. doi: 10.1016/s1473-3099(06)70521-7
  2. 2. World Health Organization. (2002) TDR Strategic Direction: Schistosomiasis. Special Programme for Research and Training in Tropical Diseases (TDR). Geneva: World Health Organization.
  3. 3. Andrade ZA (2009) Schistosomiasis and liver fibrosis. Parasite Immunol 31 (11) 656–63. doi: 10.1111/j.1365-3024.2009.01157.x
  4. 4. Cioli D, Pica-Mattoccia L, Archer S (1995) Antischistosomal drugs: past, present … and future? Pharmacol Ther 68: 35–85. doi: 10.1016/0163-7258(95)00026-7
  5. 5. Xiao SH, Catto BA, Webster LT Jr (1985) Effects of praziquantel on different developmental stages of Schistosoma mansoni in vitro and in vivo. J Infect Dis 151: 1130–1137. doi: 10.1093/infdis/151.6.1130
  6. 6. Andrew P (1985) Praziquantel: Mechanism of anti-schistosomal activity. Pharmacol vol.29 (1) 129–56. doi: 10.1016/0163-7258(85)90020-8
  7. 7. Harnett W, Kusel JR (1986) Increased exposure of parasite antigens at the surface of adult male Schistosoma mansoni exposed to praziquantel in vitro. Parasitology 93 401–405. doi: 10.1017/s0031182000051568
  8. 8. Redman CA, Robertson A, Fallon PG, Modha J, Kusel JR, et al. (1996) Praziquantel: an urgent and exciting challenge. Parasitol Today 12: 14–20. doi: 10.1016/0169-4758(96)80640-5
  9. 9. Kohn AB, Anderson PA, Roberts-Misterly JM, Greenberg RM (2001) Schistosome calcium channel beta subunits. Unusual modulatory effects and potential role in the action of the antischistosomal drug praziquantel. J Biol Chem 276: 36873–36876. doi: 10.1074/jbc.c100273200
  10. 10. Doenhoff MJ, Cioli D, Utzinger J (2008) Praziquantel: mechanisms of action,resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis 21 (6) 659–67. doi: 10.1097/qco.0b013e328318978f
  11. 11. Ribeiro F, Coelho PM, Vieira LQ, Watson DG, Kusel JR (1998) The effect of praziquantel treatment on glutathione concentration in Schistosoma mansoni. 116 229–236. doi: 10.1017/s0031182097002291
  12. 12. Oliveira FA, Kusel JR, Ribeiro F, Coelho PM (2006) Responses of the surface membrane and excretory system of Schistosoma mansoni to damage and to treatment with praziquantel and other biomolecules. Parasitology Mar;132 (Pt 3) 321–30. doi: 10.1017/s0031182005009169
  13. 13. Angelucci F, Basso A, Bellelli A, Brunori M, Pica Mattoccia L, et al. (2007) The anti-schistosomal drug praziquantel is an adenosine antagonist. Parasitology 134: 1215–21. doi: 10.1017/s0031182007002600
  14. 14. Messerli SM, Kasinathan RS, Morgan W, Spranger S, Greenberg RM (2009) Schistosoma mansoni P-glycoprotein levels increase in response to praziquantel exposure and correlate with reduced praziquantel susceptibility. Molecular & Biochemical Parasitology 167: 54–59. doi: 10.1016/j.molbiopara.2009.04.007
  15. 15. Kasinathan RS, Morgan WM, Greenberg RM (2011) Genetic knockdown and pharmacological inhibition of parasite multidrug resistance transporters disrupts egg production in Schistosoma mansoni. PLoS Negl Trop Dis 5 (12) 1425. doi: 10.1371/journal.pntd.0001425
  16. 16. Cioli D (2000) Praziquantel: is there real resistance and are there alternatives? Curr.Opin.Infect 13: 659–663. doi: 10.1097/00001432-200012000-00014
  17. 17. Fallon PG, Sturrock RF, Niang AC, Doenhoff MJ (1995) Short report: diminished susceptibility to praziquantel in a Senegal isolate of Schistosoma mansoni. Am J Trop Med Hyg 53: 61–62.
  18. 18. Stelma FF, Talla I, Sow S, Kongs A, Niang M, et al. (1995) Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni. Am J Trop Med Hyg 53: 167–170.
  19. 19. Rogers SH, Bueding E (1971) Hycanthone resistance: development in Schistosoma mansoni. Science 172: 1057–1058. doi: 10.1126/science.172.3987.1057
  20. 20. Ismail M, Botros S, Metwally A, William S, Farghally A, et al. (1999) Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am J Trop Med Hyg Jun;60 (6) 932–5.
  21. 21. Araújo N, de Souza CP, Passos LK, Simpson AJ, Dias Neto E, et al. (1996) Susceptibility to chemotherapeutic agents of Schistosoma mansoni isolates from patients treated with oxamniquine and praziquantel and not cured. Rev Soc Bras Med Trop 29 (5) 467–76. doi: 10.1590/s0037-86821996000500010
  22. 22. Coelho PM, Lima e Silva FC, Nogueira-Machado JA (1997) Resistance to oxamniquine of a Schistosoma mansoni strain isolated from patient submitted to repeated treatments. Rev Inst Med Trop 39 (2) 101–6. doi: 10.1590/s0036-46651997000200007
  23. 23. Cioli D, Botros SS, Wheatcroft-Francklow K, Mbaye A, Southgate V, et al. (2004) Determination of ED50 values for praziquantel in praziquantel-resistant and -susceptible Schistosoma mansoni isolates. Int J Parasitol 34: 979–987. doi: 10.1016/j.ijpara.2004.05.001
  24. 24. Gryseels B, Mbaye A, De Vlas SJ, Stelma FF, Guissé F, et al. (2001) Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence. Trop Med Int Health 6 (11) 864–73. doi: 10.1046/j.1365-3156.2001.00811.x
  25. 25. Doenhoff MJ, Kusel JR, Coles GC, Cioli D (2002) Resistance of Schistosoma mansoni to praziquantel: is there a problem? Trans R Soc Trop Med Hyg 96 (5) 465–9. doi: 10.1016/s0035-9203(02)90405-0
  26. 26. Fallon PG, Doenhoff MJ (1994) Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific. Am J Trop Med Hyg 51: 83–88.
  27. 27. Couto FF, Coelho PM, Araújo N, Kusel JR, Katz N, et al. (2011) Schistosoma mansoni: a method for inducing resistance to praziquantel using infected Biomphalaria glabrata snails. Mem Inst Oswaldo Cruz 106 (2) 153–7.
  28. 28. Durand P, Sire C, Théron A (2000) Isolation of microsatellite markers in the digenetic trematode Schistosoma mansoni from Guadeloupe island. Mol Ecol 9 (7) 997–8. doi: 10.1046/j.1365-294x.2000.00939-4.x
  29. 29. Criscione CD, Valentim CL, Hirai H, LoVerde PT, Anderson TJ (2009) Genomic linkage map of the human blood fluke Schistosoma mansoni. Genome Biol 10 (6) R71. doi: 10.1186/gb-2009-10-6-r71
  30. 30. Rodrigues NB, Coura FP, De Souza CP, Jannoti Passos LK, Dias-Neto E, et al. (2002a) Populational structure of Schistosoma mansoni assessed by DNA microsatellites. Int J Parasitol 32: 843–851. doi: 10.1016/s0020-7519(02)00031-0
  31. 31. Curtis J, Sorensen RE, Minchella DJ (2002) Schistosome genetic diversity: theimplications of population structure as detected with microsatellite markers. Parasitology 125 Suppl: S51–9. doi: 10.1017/s0031182002002020
  32. 32. Agola LE, Mburu DN, DeJong RJ, Mungai BN, Muluvi GM, et al. (2006) Microsatellite typing reveals strong genetic structure of Schistosoma mansonifrom localities in Kenya. Infect Genet Evol Nov;6 (6) 484–90. doi: 10.1016/j.meegid.2006.03.002
  33. 33. Agola LE, Steinauer ML, Mburu DN, Mungai BN, Mwangi IN, et al. (2009) Genetic diversity and population structure of Schistosoma mansoni within human infrapopulations in Mwea, central Kenya assessed by microsatellite markers. Acta Trop Sep;111 (3) 219–25. doi: 10.1016/j.actatropica.2009.04.012
  34. 34. Gower CM, Gouvras AN, Lamberton PH, Deol A, Shrivastava J, et al. (2012) Population genetic structure of Schistosoma mansoni and Schistosoma haematobium from across six sub-Saharan African countries: Implications for epidemiology, evolution and control. Acta Trop 128: 261–274. doi: 10.1016/j.actatropica.2012.09.014
  35. 35. Steinauer ML, Hanelt B, Agola LE, Mkoji GM, Loker ES (2009) Genetic structure of Schstosoma mansoni in western Kenya: the effects of geography and host sharing. Int J Parasitol Oct;39 (12) 1353–62. doi: 10.1016/j.ijpara.2009.04.010
  36. 36. Norton AJ, Gower CM, Lamberton PH, Webster BL, Lwambo NJ, et al. (2010) Genetic consequences of mass human chemotherapy for Schistosoma mansoni: population structure pre- and post-praziquantel treatment in Tanzania. Am J Trop Med Hyg 83 (4) 951–7. doi: 10.4269/ajtmh.2010.10-0283
  37. 37. French MD, Churcher TS, Basáñez MG, Norton AJ, Lwambo NJ, et al. (2012) Reductions in genetic diversity of Schistosoma mansoni populations under chemotherapeutic pressure: The effect of sampling approach and parasite population definition. Acta Trop Mar 15. doi: 10.1016/j.actatropica.2012.03.001
  38. 38. Feng Z, Curtis J, Minchella DJ (2001) The influence of drug treatment on the maintenance of schistosome genetic diversity. J Math Biol 43 (1) 52–68. doi: 10.1007/s002850100092
  39. 39. Gentile R, Oliveira G (2008) Brazilian studies on the genetics of Schistosoma mansoni. Acta Trop 108 (2–3) 175–8. doi: 10.1016/j.actatropica.2008.09.003
  40. 40. Pellegrino J, Katz N (1968) Experimental chemotherapy of Schistosomiasis mansoni. Adv Parasitol 6: 233–290. doi: 10.1016/s0065-308x(08)60475-3
  41. 41. Pellegrino J (1956) Siqueira A (1956) Técnica de perfusão para colheita de Schistosoma mansoni em cobaias experimentalmente infestadas. Revista Brasileira de Malacologia e Doenças Tropicais 589–597.
  42. 42. Rodrigues NB, LoVerde PT, Romanha AJ, Oliveira G (2002b) Characterization of new Schistosoma mansoni microsatellite loci in sequences obtained from public DNA databases and microsatellite enriched genomic libraries. Mem Inst Oswaldo Cruz 97: 71–75. doi: 10.1590/s0074-02762002000900015
  43. 43. Rodrigues NB, Silva MR, Pucci MM, Minchella DJ, Sorensen RE, et al. (2007) Microsatellite enriched genomic libraries as a source of polymorphic loci for Schistosoma mansoni. Mol Ecol Notes 7: 263–265. doi: 10.1111/j.1471-8286.2006.01575.x
  44. 44. Goudet J (2001) FSTAT, a program to estimate and test gene diversities and fixation indices (version 2.9.3). Available: http://www.unil.ch/izea/softwares/ Fstat.html. Updated from Goudet (1995).
  45. 45. Schneider S. (2000) A software for population genetic data analylis. Arlequin ver 2.000, Genetics and biometry laboratory. University of Geneva, Switzerland.
  46. 46. Wright S (1921) Systems of mating. Genetics 6: 111–178.
  47. 47. Nei M (1977) F-statistics and analysis of gene diversity in subdivided populations. Ann Hum Genet 41 (2) 225–33. doi: 10.1111/j.1469-1809.1977.tb01918.x
  48. 48. Slatkin M (1995) A measure of population subdivision based on microsatellite allele frequencies. Genetics 139: 457–462.
  49. 49. Guo SW (1992) Thompson EA (1992) Performing the exact test of Hardy-Weinberg. Proportion for multiple Aleles. Biometrics 48: 361–372. doi: 10.2307/2532296
  50. 50. Delgado VS, Suárez DP, Cesari IM, Incani RN (1992) Experimental chemotherapy of Schistosoma mansoni with praziquantel and oxamniquine: differential effect of single or combined formulations of drugs on various strains and on both sexes of the parasite. Parasitol Res 78 (8) 648–54. doi: 10.1007/bf00931515
  51. 51. Shaw MK, Erasmus DA (1987) Schistosoma mansoni: structural damage and tegumental repair after in vivo treatment with praziquantel. Parasitology 94 (Pt 2) 243–54. doi: 10.1017/s0031182000053920
  52. 52. Pica-Mattoccia L, Cioli D (2004) Sex- and stage-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquantel treatment. Int J Parasitol 34: 527–533. doi: 10.1016/j.ijpara.2003.12.003
  53. 53. William S, Sabra A, Ramzy F, Mousa M, Demerdash Z, et al. (2001) Stability and reproductive fitness of Schistosoma mansoni isolates with decreased sensitivity to praziquantel. International Journal for Parasitology 31: 1093–1100. doi: 10.1016/s0020-7519(01)00215-6
  54. 54. Zerlotini A, Heiges M, Wang H, Moraes RL, Dominitini AJ, et al. (2009) SchistoDB: a Schistosoma mansoni genome resource. Nucleic Acids Res 37: D579–582. doi: 10.1093/nar/gkn681